The use of wild-type NGF in the clinical setting to investigate human NGF as a treatment for diabetic polyneuropathy and peripheral neuropathies in HIV led to trial discontinuation, after reports of a potent dose-dependent hyperalgesia, such as back pain, injection site hyperalgesia, and severe myalgia (Apfel, 1999a,b, 2002). Here, NGF is linked to diabetic neuropathy.